TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00725075
Drug: MK-8435 (Org 25935) 12-16 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally BID for a final concentration of 24-32 mg/day
Study: NCT02903680
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline 0,9% same volume
Study: NCT03823612
Drug: GC tooth mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
Study: NCT02727283
Drug: GSK3179106
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
Study: NCT02727283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
Study: NCT02326779
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
Study: NCT02100917
Drug: DMB-3111
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02579733
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02579733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01405248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/time per os three times a day. 180days
Study: NCT03174522
Drug: REX-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: REX-001 is administered through an intra-arterial catheter.
Study: NCT03174522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered through an intra-arterial catheter.
Study: NCT01818232
Drug: [14C]-LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00352105
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg.m2/d IV continuous x 4 days
Study: NCT01505907
Drug: CXB909
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXB909
Study: NCT02889432
Drug: Oral Melatonin 10mg
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02889432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03667703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to either receive a placebo or famotidine (study drug).
Study: NCT00311467
Drug: Capecitabine, Interferon, Interleukin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups
Study: NCT06517134
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of antihypertensive drugs
Study: NCT01843855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A saline infusion will be given to match the study drug infusion.
Study: NCT00866307
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00866307
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00866307
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00866307
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and PO
Study: NCT01585792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01804244
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 25-mg tablet \[27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
Study: NCT00538031
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00671255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
Study: NCT00538031
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01902550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
Study: NCT01167829
Drug: Oral Testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
Study: NCT00713583
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 800mg levodopa and 200mg carbidopa per day
Study: NCT04870879
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT00767897
Drug: Human Papillomavirus Vaccine
Normalized name: human papillomavirus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
Study: NCT00802685
Drug: Early ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen.
Study: NCT04506372
Drug: Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
Study: NCT03800875
Drug: 27-hour inpatient intervention
Normalized name: Impatiens Balsamina Leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
Study: NCT02271412
Drug: LY03005
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
Study: NCT02271412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01545700
Drug: Control-saline
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomized to receive saline 2 cc
Study: NCT01545700
Drug: Control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomized to receive saline 2 cc
Study: NCT03861143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily tablet
Study: NCT00281879
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
Study: NCT00281879
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered on days +1, +3, and +7.
Study: NCT05043467
Drug: Duvie(Lobeglitazone) tab 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
Study: NCT01777581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01101503
Drug: Intensive multifactorial group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c \>=5.5%and \<=6.0%,fasting blood glucose \>=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose \>= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin.
Study: NCT01101503
Drug: conventional multifactorial therapy group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c \>6.5%and \<=7.0%,fasting blood glucose \>6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose \> 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \> 1.9 mmol/L and \< =2.5 mmol/L, triglyceride \> 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin.
Study: NCT04312698
Drug: D013, D326, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
Study: NCT04312698
Drug: placebo of D013, D326, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
Study: NCT04312698
Drug: D013, placebo of D326, placebo of D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
Study: NCT04188184
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
Study: NCT01972893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.
Study: NCT00590590
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: semi solid, twice weekly for 4 months
Study: NCT00625092
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post-operative day 1 and day 2, 600mg/m\^2 intraperitoneal (IP) held for 23 hours
Study: NCT00625092
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 0 200 mg/m\^2 intraperitoneal held for 2 hours
Study: NCT01863511
Drug: loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03847987
Drug: RO7017773 Phase II Tablet Unflavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
Study: NCT03847987
Drug: RO7017773 Phase II Tablet Sweetened/Flavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
Study: NCT00356278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in the same manner as the active drugs.
Study: NCT00647556
Drug: tretinoin 0.05% emollient cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied topically once daily in the evening
Study: NCT00616863
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04342663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
Study: NCT00404963
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00404963
Drug: GSK376501
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03365466
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH 5000u IH qd
Study: NCT04316585
Drug: GSK2982772
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.
Study: NCT04316585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 matching placebo tablets will be administered via the oral route.
Study: NCT00541931
Drug: Dietary Supplement: LifePak Nano
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use
Study: NCT00959231
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02814565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine HCl extended release placebo-matching capsules
Study: NCT02113735
Drug: H.P. Acthar® Gel (repository corticotropin injection)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02113735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01340209
Drug: Placebo Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium placebo once daily delivered with Respimat inhaler
Study: NCT03690765
Drug: Duphaston® (Dydrogesterone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
Study: NCT03690765
Drug: Duphaston® (Dydrogesterone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
Study: NCT01165047
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
Study: NCT01875562
Drug: Qishe Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill, 3.75 g, twice per day, four weeks
Study: NCT02805166
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00284791
Drug: Fluoxetine (drug)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03904329
Drug: Oral Anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets of anti coagulations either warfare or NOACs
Study: NCT02163018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of increasing doses of placebo
Study: NCT03520036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD, oral, 16 weeks
Study: NCT01227421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, (2 tablets) twice daily with food for 5 days
Study: NCT02288338
Drug: 1 (Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 1 (Lipitor®, Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 2 (Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 2(Lipitor®, Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 2 (Lipitor®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 4 (Lipitor®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 4(Lipitor®, Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 4 (Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 5 (Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 5 (Lipitor®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 5 (Lipitor®, Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT02288338
Drug: 6(Lipitor®, Ezetrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study: NCT00000559
Drug: estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01507272
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
Study: NCT00312910
Drug: Probiotics-Bio-plus
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02706873
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule or Tablet; Oral
Study: NCT02706873
Drug: Placebo to Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule or Tablet; Oral
Study: NCT01898065
Drug: 18-F-MISO
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET scan with the 18 Fluoro Misonidazole
Study: NCT01241214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered twice daily.
Study: NCT02373280
Drug: 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
Study: NCT02373280
Drug: 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the participants received PPI based triple therapy\[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\]